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introduction
Primary hypothyroidism results from under-secretion of thyroid 
hormones from the thyroid gland. The most common cause 
of primary hypothyroidism is chronic autoimmune thyroiditis 
(Hashimoto’s Disease). Other causes include throidectomy, 
thyroid gland ablation with radioactive iodine, external 
irradiation, a biosynthetic defect in iodine organification, 
thyroid lymphoma and drug-induced. Signs and symptoms are 
generally related to the duration and severity of hypothyroidism, 
the rapidity with which hypothyroidism occurs, and the 
psychological characteristics of the patient. Hypothyroid 
patients usually present dry skin, cold sensitivity, fatigue, muscle 
cramps, voice changes and constipation.1
Increased thyroid stimulating hormone (TSH) values usually 
indicate hypothyroidism whilst decreased values usually indicate 
hyperthyroidism. This test has proved to be both sensitive and 
specific for hypothyroidism.  An elevated TSH level with a 
normal free T4 level is referred to as subclinical hypothyroidism.  
It is important to note that patients with subclinical 
hypothyroidism may still have clinical symptoms.2 In general, 
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abstract
The study aims to identify and recommend ways of 
improving thyroid function monitoring. Over a three month 
period, eighty-eight patients with clinical and subclinical 
primary hypothyroidism on long-term levothyroxine therapy 
were seen by GPs at the Chronic Disease Managment 
Clinic. The monitoring intervals of thyroid function tests 
for patients with controlled and uncontrolled primary 
hypothyroidism were benchmarked with the American 
Association of Clinical Endocrinologists guidelines.
The overall average compliance for clinical hypothyroid 
cases was 69% (n=15) and 40% (n=9) for the subclinical 
hypothyroid cases. In the clinical hypothyroid cases 
compliance was 71% (n=15) and 67% (n=14) for controlled 
and uncontrolled cases, respectively. In the subclinical 
hypothyroid cases compliance was 43% (n=10) and 35% 
(n=8) for controlled and uncontrolled cases, respectively.  
Knowledge of the guidelines amongst GPs should be 
increased especially when it comes to the management of 
subclinical hypothyroidism, and in cases of uncontrolled 
hypothyroidism in general. This is possible through better 
dissemination, availability and reinforcement of such 
guidelines.
hypothyroidism can be adequately treated with a constant daily 
dose of levothyroxine,  usually with a single maintenance dose of 
100-200 mcg.3,4
TSH levels are the best indicator of thyroid function and 
the best test for monitoring response to levothyroxine therapy.5 
It has been found that adverse events related to replacement 
therapy with levothyroxine are more common in patients who 
do not receive the recommended monitoring.6   Therefore, 
monitoring of thyroid function tests (TFTs) has a role to gauge 
the thyroid function response to levothyroxine, ensuring the 
minimum effective dose at the least adverse drug effects.
aims
•	 To evaluate the adequacy of thyroid function test (TFT) 
monitoring in patients with primary hypothyroidism that 
are on levothyroxine therapy.
•	 To recommend ways in which TFT monitoring can be 
improved.
method
settinG and samplinG
An audit was conducted in a Primary Care setting at Qormi 
Health Centre from July till September 2015. The reason 
for conducting the study solely at the Qormi Health Centre 
was that during the study period, the only Chronic Disease 
Management Clinic (CDMC) was located at that centre. All 
patients with clinical and subclinical primary hypothyroidism, 
that were on long term levothyroxine (for more than 3 months), 
were identified from the CDMC by the ten GPs that practice 
in this clinic. The cohort amounted to eighty-eight patients. 
The study excluded hypothyroid patients that had disturbances 
of hypothalamic-pituitary function and females that were 
pregnant. With regards to subclinical hypothyroid patients, only 
those with TSH levels > 10 micro IU/ml were considered, as data 
for patients with mildly raised TFTs is controversial.1
Hypothyroid patients, including those diagnosed with 
subclinical hypothyroidism, were identified by the GPs that 
regularly follow patients at the CDMC. For each patient, the 
ID number and date of visit of the patient were recorded by 
the GPs on a data sheet which was distributed prior to the 
commencement of the study. For each patient, iSOFT clinical 
manager was then used to identify the TFT results over the 
previous year. The time interval between TFT monitoring for 
controlled and uncontrolled thyroid function for both clinical 
and subclinical hypothyroid patients was recorded.
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standards
The standard criteria established by the AACE (last updated in 
2012) are as follows:
1. Well-controlled subclinical hypothyroid patients (normal 
TSH) should have their TFT monitored every 48 weeks.
2. Patients with uncontrolled subclinical hypothyroidism or 
patients who experienced a change in levothyroxine dose 
should have their TFT checked every 6-8 weeks.
3. Well-controlled clinical hypothyroid patients (normal TSH 
levels) should have a TFT repeated at 24 weeks and the 2nd 
TFT at 48 weeks.
4. Patients with uncontrolled clinical hypothyroidism, or 
patients who experienced a change in levothyroxine dose 
should have the TFT repeated at least 6 weeks after a 
deranged TSH level, or dose adjustment, respectively.
data analysis
All data were processed using Microsoft Excel 2013. The data 
were then analysed by recording the TSH monitoring intervals 
for patients with subclinical/clinical hypothyroidism with 
normal/abnormal TFTs. Compliance with AACE guideline 
criteria was recorded for each category.
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results
48% (42 from 88 patients) studied had clinical hypothyroidism, 
whilst 52% (n=46) had subclinical hypothyroidism (Figure 1).
In controlled clinical hypothyroid cases 71% (n=15) 
compliance to the recommended TFT monitoring interval, 
as per AACE guidelines, was observed (Figure 2) whilst for 
uncontrolled cases compliance was 67% (n=14) (Figure 3). 
In controlled subclinical cases there was 43% (n=10) 
compliance to the recommended TFT monitoring interval, 
whilst for those with abnormal TFTs there was 35% (n=8) 
compliance to the recommended monitoring interval (Figures 4 
and 5 respectively).  
When considering both controlled and uncontrolled cases, 
the overall average compliance for clinical and subclinical 
hypothyroid cases were 69% (n=15), and 39% (n=9) respectively. 
This was achieved by calculating the mean of the compliance 
for controlled and uncontrolled cases in both clinical ((71% + 
67%)/2) and subclinical hypothyroid ((43% + 35%)/2) cases.
discussion
In this study all patients with hypothyroidism were on 
levothyroxine treatment. Since downward dose adjustment or 
even cessation of levothyroxine therapy may be required, T4 
and TSH monitoring is necessary for the management of both 
clinical and subclinical hypothyroidism.
For both controlled and uncontrolled hypothyroid cases 
compliance to the thyroid monitoring guidelines was noted 
to be greater for patients with clinical hypothyroidism (69%) 
Figure 1: Total number of clinical and subclinical hypothyroid cases
Figure 2: Compliance to recommended TFT monitoring interval in 
clinical cases with controlled thyroid function
Figure 3: Compliance to recommended TFT monitoring interval in 
clinical cases with uncontrolled thyroid function
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Figure 4: Compliance to recommended TFT monitoring interval in 
subclinical cases with controlled thyroid function
Figure 5: Compliance to recommended TFT monitoring interval in 
subclinical cases with uncontrolled thyroid function
Figure 6: Percentage compliance to recommended intervals for 
TFT monitoring in controlled and uncontrolled clinical and 
subclinical hypothyroidism
re
fer
en
ce
s c
an
 be
 ac
ce
ss
ed
 on
 th
es
yn
ap
se
.ne
t
than for those with subclinical hypothyroidism (40%). The 
most probable reason for this is that physicians are more 
aware of thyroid monitoring frequency guidelines for clinical 
hypothyroid cases. Furthermore, physicians may have 
experienced difficulties in interpreting subclinical hypothyroid 
biochemical derangements and thereby in differentiating it 
from clinical hypothyroidism. Delayed monitoring was noted 
whenever physicians showed non-compliance in both patient 
categories with normal and abnormal TFT results. This is 
contrary to what is normally expected since uncontrolled 
hypothyroid cases require shorter interval monitoring times, 
hence a stricter monitoring approach.
The results show that physicians are not aware of the 
clinical importance of adequately monitoring subclinical 
hypothyroidism, with more importance being given to clinical 
hypothyroidism. Regular monitoring of TSH levels in primary 
care patients can be ensured through a computer-generated 
recall system with written notification to patients.7
limitations
The main limitation of the audit was the small sample size 
which may have led to inaccuracies in the interpretation of the 
results. In most cases no documentation was found with regards 
to changes in levothyroxine dose, hence it was assumed that a 
change in dose was made with every deranged TFT result. Data 
was only collected by GPs working at the Qormi Health Centre, 
and hence the data may not truly represent compliance to the 
guidelines in patients attending other health centres. The audit 
did not assess the possible reasons for abnormal TSH levels, for 
example pregnancy, medication interactions and compliance to 
levothyroxine therapy.
conclusion and recommendations
This audit has shown that there is room for improvement when 
it comes to thyroid function monitoring, especially in cases of 
subclinical hypothyroidism. Physicians should be more aware 
of the biochemical derangements that correlate to subclinical 
hypothyroidism which will enable them to differentiate it from 
clinical hypothyroidism. Whilst excessive monitoring leads to 
unnecessary visits by patients and increased expenditure, on the 
other hand, delayed monitoring may lead to inaccurate dosing 
of levothyroxine and hence possibly increased adverse effects 
and/or ineffective thyroid function control. 
In order to improve compliance to the AACE guidelines, it 
is recommended that they should be well-disseminated both 
at Mater Dei Hospital medical outpatients clinic and at health 
centres (where many patients have their thyroid function 
monitored). Knowledge of the guidelines especially amongst 
GPs can be increased by means of seminars and conferences 
given by endocrinologists. A downloadable PDA version and 
availability of the guidelines on KURA would also help to 
improve compliance. 
15Volume 15, 2016  Issue 02
